Saluda Medical, Inc. (ASX:SLD)
Australia flag Australia · Delayed Price · Currency is AUD
0.4000
-0.0100 (-2.44%)
At close: Sep 22, 2026

Saluda Medical Stock Forecast

Stock Price Forecast

According to 3 analysts polled by S&P Global, Saluda Medical stock has a consensus rating of "Strong Buy" and an average price target of $1.95. The average 1-year stock price forecast is 387.50% higher than the current stock price, while the lowest is $1.61 (+302.50%) and the highest is $2.20 (+450.00%).

Price Target: $1.95 (+387.50%)
Analyst Consensus: Strong Buy

Price Target

Chart
TargetLowAverageMedianHigh
Price$1.61$1.95$2.04$2.20
Change+302.50%+387.50%+410.00%+450.00%

Analyst Ratings

The average analyst rating for Saluda Medical stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.

Recommendation Trends

Chart
RatingApr '26May '26Jun '26Jul '26Aug '26Sep '26
Strong Buy222333
Buy000000
Hold000000
Sell000000
Strong Sell000000
Total222333

Financial Forecast

Revenue This Year
119.74M
from 90.18M
Increased by 32.79%
Revenue Next Year
181.59M
from 119.74M
Increased by 51.65%
EPS This Year
-0.50
from -9.38
EPS Next Year
-0.28
from -0.50
Fiscal YearFY 2023FY 2024FY 2025FY 2026FY 2027
Period EndingJun 30, 2023Jun 30, 2024Jun 30, 2025Jun 30, 2026Jun 30, 2027
Revenue
22.23M51.68M70.36M90.18M119.74M
Revenue Growth
-132.45%36.13%28.17%32.79%
Gross Profit
4.04M23.11M32.76M44.08M61.85M
Gross Margin
18.17%44.72%46.56%48.89%51.65%
Operating Income
-92.22M-99.14M-118.05M-144.49M-130.47M
Net Income
-92.16M-97.83M-149.30M-149.57M-149.90M
EPS
----9.38-0.50
Free Cash Flow
----116.72M-128.15M
No. Analysts
----3
EPS and Forward PE are based on non-GAAP adjusted numbers.

Revenue Forecast

Revenue202720282029
High119.9M
Avg119.7M
Low119.6M

Revenue Growth

Revenue Growth202720282029
High
33.0%
Avg
32.8%
Low
32.6%

EPS Forecast

EPS202720282029
High-0.37
Avg-0.50
Low-0.63

EPS Growth

EPS Growth202720282029
High-
Avg-
Low-